Actos May Cut Heart Attack Risk in Diabetes Patients
Posted on: Thursday, 14 September 2006, 15:01 CDT
Takeda's diabetic drug Actos may have benefits beyond glycemic control and reduce the risk of heart attack and strokes in patients with type two diabetes, according to a study.
Takeda said that study data shows that Actos can have a positive effect on several measures of cardiovascular disease outcomes in high-risk patients with type two diabetes.
In the study, the incidence of recurrent stroke was reduced by 47% and the combined risk of death, heart attack, or stroke was reduced by 28% in patients who received Actos.
"Because they are at higher risk, it is important to find solutions that impact not only glycemic control but overall cardiovascular health. These findings show the potential benefits Actos can have in managing diabetes and the risk factors that contribute to cardiovascular disease," said Dr Robert Spanheimer, senior medical director for diabetes and metabolism at Takeda Pharmaceuticals.
Source: Datamonitor
Related Articles
- Statins May Prevent Blood Clots In Patients With Cardiovascular Disease
- Short-Term Hormone Therapy Plus Radiation Ups Survival For Medium-Risk Prostate Cancer Patients
- Diabetes Prevention Trial Enrolls First Patients; Study Seeks Additional Volunteers in California, Texas, Louisiana
- Is There a Link Between Obesity, Diabetes, Erectile Dysfunction and Cardiovascular Disease?
- Covalent Group, Inc. Signs $2.2 Million Contract With New Sponsor to Conduct Clinical Trial in Patients With Cardiovascular Disease
- Roller coasters raise risk in heart patients: study
- Roller coasters raise risk in heart patients-study
- 'Real Life' Study Clarifies Risk of Recurrence for High-Risk Breast Cancer Patients
- Sex Disparities in Treatment of Cardiac Risk Factors in Patients With Type 2 Diabetes
- The ORLIstat and CArdiovascular Risk Profile in Patients With Metabolic Syndrome and Type 2 DIAbetes (ORLICARDIA) Study
 |
 |
User Comments (0)
RSS Feeds